CN115054698B - 包封选择性atp抑制剂的环糊精组合物及其应用 - Google Patents

包封选择性atp抑制剂的环糊精组合物及其应用 Download PDF

Info

Publication number
CN115054698B
CN115054698B CN202210378454.7A CN202210378454A CN115054698B CN 115054698 B CN115054698 B CN 115054698B CN 202210378454 A CN202210378454 A CN 202210378454A CN 115054698 B CN115054698 B CN 115054698B
Authority
CN
China
Prior art keywords
cyclodextrin
brpa
composition
cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210378454.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN115054698A (zh
Inventor
J-F.格施温德
S.加纳帕蒂-坎尼亚庞
S.苏
B.沃格斯泰恩
K.W.金兹勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to CN202210378454.7A priority Critical patent/CN115054698B/zh
Publication of CN115054698A publication Critical patent/CN115054698A/zh
Application granted granted Critical
Publication of CN115054698B publication Critical patent/CN115054698B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202210378454.7A 2014-01-14 2015-01-14 包封选择性atp抑制剂的环糊精组合物及其应用 Active CN115054698B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210378454.7A CN115054698B (zh) 2014-01-14 2015-01-14 包封选择性atp抑制剂的环糊精组合物及其应用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461927259P 2014-01-14 2014-01-14
US61/927259 2014-01-14
US201461992572P 2014-05-13 2014-05-13
US61/992572 2014-05-13
PCT/US2015/011344 WO2015108933A1 (en) 2014-01-14 2015-01-14 Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
CN201580013842.3A CN106102725A (zh) 2014-01-14 2015-01-14 包封选择性atp抑制剂的环糊精组合物及其应用
CN202210378454.7A CN115054698B (zh) 2014-01-14 2015-01-14 包封选择性atp抑制剂的环糊精组合物及其应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580013842.3A Division CN106102725A (zh) 2014-01-14 2015-01-14 包封选择性atp抑制剂的环糊精组合物及其应用

Publications (2)

Publication Number Publication Date
CN115054698A CN115054698A (zh) 2022-09-16
CN115054698B true CN115054698B (zh) 2024-11-08

Family

ID=53543385

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210378454.7A Active CN115054698B (zh) 2014-01-14 2015-01-14 包封选择性atp抑制剂的环糊精组合物及其应用
CN201580013842.3A Pending CN106102725A (zh) 2014-01-14 2015-01-14 包封选择性atp抑制剂的环糊精组合物及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580013842.3A Pending CN106102725A (zh) 2014-01-14 2015-01-14 包封选择性atp抑制剂的环糊精组合物及其应用

Country Status (7)

Country Link
US (3) US9737487B2 (OSRAM)
EP (1) EP3094317B1 (OSRAM)
JP (1) JP6552509B2 (OSRAM)
CN (2) CN115054698B (OSRAM)
AU (1) AU2015206629B2 (OSRAM)
CA (1) CA2936940C (OSRAM)
WO (1) WO2015108933A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010021750A2 (en) 2008-08-21 2010-02-25 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
US10751306B2 (en) 2015-11-06 2020-08-25 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
WO2018152332A1 (en) * 2017-02-15 2018-08-23 Henry Ford Health System Applications of pair-production for improved radiotherapy
JP7670278B2 (ja) 2019-10-04 2025-04-30 国立大学法人 熊本大学 薬物キャリア剤及びその製造方法
WO2021072256A1 (en) * 2019-10-11 2021-04-15 Dentosity, Llc Improved light-based dental treatment device
AU2021338594A1 (en) * 2020-09-08 2023-04-13 The Johns Hopkins University Encapsulated agents that bind to MCT-1
WO2023102496A1 (en) * 2021-12-03 2023-06-08 Path Encapsulated pharmaceutical compositions, related methods of making, and related methods of treatment
WO2024243178A1 (en) * 2023-05-22 2024-11-28 The Johns Hopkins University Cyclodextrin compositions encapsulating alkylating agents and uses thereof
WO2024246220A1 (en) * 2023-05-31 2024-12-05 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102131389A (zh) * 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337760A (en) 1978-10-13 1982-07-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
DE3360633D1 (en) 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US5800820A (en) 1989-01-10 1998-09-01 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
AU6676396A (en) 1995-07-14 1997-02-18 Johns Hopkins University, The Tumor type ii hexokinase transcription regulatory regions
US5854067A (en) 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US6284786B1 (en) 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
US20020006915A1 (en) 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US6448030B1 (en) 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
AU2001245766A1 (en) 2000-03-14 2001-09-24 The Johns Hopkins University School Of Medicine Arrest of proliferation of highly glycolytic tumors
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
AU2002233916A1 (en) 2000-08-03 2002-04-29 Albert Einstein College Of Medicine Isocitrate lyase enzyme from mycobacterium tuberculosis and inhibitory agents to combat persistent infection
US7381713B2 (en) 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
EP1526865A4 (en) 2002-08-05 2009-09-02 Mirus Bio Corp COMPOUNDS FOR TARGETING HEPATIC CELLS
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
AU2004206870A1 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia using energolytic agents
WO2006010073A1 (en) 2004-07-08 2006-01-26 Threshold Pharmaceuticals, Inc. Prevention of cancer
CA2575367A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
US7754693B2 (en) 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
US8778410B2 (en) 2008-02-19 2014-07-15 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
WO2010021750A2 (en) * 2008-08-21 2010-02-25 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
WO2012047339A2 (en) * 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
US20150337121A1 (en) * 2012-06-26 2015-11-26 The Johns Hopkins University Multifunctional tunable biomaterials for tissue engineering

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102131389A (zh) * 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法

Also Published As

Publication number Publication date
JP2017502984A (ja) 2017-01-26
CA2936940C (en) 2023-07-04
US20160015639A1 (en) 2016-01-21
WO2015108933A1 (en) 2015-07-23
AU2015206629B2 (en) 2020-03-05
US20190328666A1 (en) 2019-10-31
US9737487B2 (en) 2017-08-22
EP3094317B1 (en) 2019-10-02
AU2015206629A1 (en) 2016-08-25
CN106102725A (zh) 2016-11-09
US20180008541A1 (en) 2018-01-11
CA2936940A1 (en) 2015-07-23
EP3094317A4 (en) 2017-11-22
CN115054698A (zh) 2022-09-16
JP6552509B2 (ja) 2019-07-31
EP3094317A1 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
CN115054698B (zh) 包封选择性atp抑制剂的环糊精组合物及其应用
ES2793673T3 (es) Agente de direccionamiento para células cancerosas o fibroblastos asociados con cáncer
JP2022081527A (ja) 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用
US20220249438A1 (en) Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells
TR202018770A2 (tr) Platine Dirençli Over Kanseri Tedavisine Yönelik Yeni Bir İlaç Taşıyıcı Sistem
HK40081533B (zh) 包封选择性atp抑制剂的环糊精组合物及其应用
HK40081533A (en) Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
US20230338297A1 (en) Encapsulated Agents that Bind to MCT-1
HK1230950A1 (en) Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
WO2024243178A1 (en) Cyclodextrin compositions encapsulating alkylating agents and uses thereof
JPWO2006035515A1 (ja) 膀胱表在性癌の治療又は予防用医薬組成物、及びその利用
Chapiro et al. Systemic Delivery of Microencapsulated 3-Bromopyruvate for

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081533

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant